Reproxalap - Aldeyra Therapeutics

Drug Profile

Reproxalap - Aldeyra Therapeutics

Alternative Names: ADX 102; NS 2; NS-2-Aldeyra

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aldeyra Therapeutics
  • Class Anti-inflammatories; Eye disorder therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunosuppressants; Malondialdehyde inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sjogren-Larsson syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Uveitis
  • Phase II Allergic conjunctivitis; Dry eyes; Sjogren-Larsson syndrome
  • Preclinical Contact dermatitis; Inborn error metabolic disorders; Inflammation; Mucositis

Most Recent Events

  • 05 Dec 2017 Chemical structure information added
  • 11 Oct 2017 Efficacy data from a phase IIb trial in Allergic conjunctivitis released by Aldeyra Therapeutics
  • 10 Oct 2017 Aldeyra Therapeutics plans a phase III trial for Allergic conjunctivitis in the first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top